We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Teladoc (TDOC - Free Report) closed the most recent trading day at $202.66, moving -1.35% from the previous trading session. This change lagged the S&P 500's daily loss of 1.16%. Meanwhile, the Dow lost 1.84%, and the Nasdaq, a tech-heavy index, lost 0.13%.
Heading into today, shares of the telehealth services provider had lost 5.94% over the past month, lagging the Medical sector's loss of 0.29% and the S&P 500's loss of 1.96% in that time.
TDOC will be looking to display strength as it nears its next earnings release. In that report, analysts expect TDOC to post earnings of -$0.34 per share. This would mark year-over-year growth of 12.82%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $281.34 million, up 103.91% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.40 per share and revenue of $990.71 million. These totals would mark changes of -1.45% and +79.05%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for TDOC. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.56% higher. TDOC is currently a Zacks Rank #4 (Sell).
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 166, putting it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TDOC in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
Teladoc (TDOC - Free Report) closed the most recent trading day at $202.66, moving -1.35% from the previous trading session. This change lagged the S&P 500's daily loss of 1.16%. Meanwhile, the Dow lost 1.84%, and the Nasdaq, a tech-heavy index, lost 0.13%.
Heading into today, shares of the telehealth services provider had lost 5.94% over the past month, lagging the Medical sector's loss of 0.29% and the S&P 500's loss of 1.96% in that time.
TDOC will be looking to display strength as it nears its next earnings release. In that report, analysts expect TDOC to post earnings of -$0.34 per share. This would mark year-over-year growth of 12.82%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $281.34 million, up 103.91% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.40 per share and revenue of $990.71 million. These totals would mark changes of -1.45% and +79.05%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for TDOC. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.56% higher. TDOC is currently a Zacks Rank #4 (Sell).
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 166, putting it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TDOC in the coming trading sessions, be sure to utilize Zacks.com.